Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Castagna, Luca  [Clear All Filters]
2014
Sala E, Crocchiolo R, Gandolfi S, Ventre MBruno, Bramanti S, Peccatori J, Sarina B, Corti C, Ciceri F, Santoro A, et al. Bendamustine combined to donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014.
2015
El-Cheikh J, Crocchiolo R, Vai A, Furst S, Bramanti S, Sarina B, Granata A, Faucher C, Mohty B, Harbi S, et al. Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide. Mediterr J Hematol Infect Dis. 2015;7(1):e2015048.
Castagna L, Carlo-Stella C, Mazza R, Santoro A. Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2015;7(1):e2015015.
Blaise D, Furst S, Crocchiolo R, El-Cheikh J, Granata A, Harbi S, Bouabdallah R, Devillier R, Bramanti S, Lemarie C, et al. Haploidentical T-cell replete transplantation with post-transplant cyclophosphamide for patients in or above the 6(th) decade of age compared with allogeneic hematopoietic stem cell transplantation from an HLA-matched related or unrelated donor. Biol Blood Marrow Transplant. 2015.
2016
Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VRuggero, Salvi F, Merli F, Anastasia A, Luminari S, et al. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. J Clin Oncol. 2016.
Crocchiolo R, Giordano L, Rimondo A, Bologna M, Sarina B, Morabito L, Bramanti S, Castagna L, Mineri R. Human Herpesvirus 6 replication predicts Cytomegalovirus reactivation after allogeneic stem cell transplantation from haploidentical donor. J Clin Virol. 2016;84:24-26.
2018
Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs KS, Afanasyev B, Díez-Martín JL, Corradini P, et al. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer. 2018.
Cauchois R, Castagna L, Pagliardini T, Harbi S, Calmels B, Bramanti S, Granata A, Lemarie C, Maisano V, Legrand F, et al. Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3 cells. Br J Haematol. 2018.
2019
Bramanti S, Calafiore V, Longhi E, Mariotti J, Crespiatico L, Sarina B, De Philippis C, Nocco A, Santoro A, Castagna L. Donor specific anti-HLA antibodies (DSA) in Haploidentical stem cell transplantation with Post Transplant Cyclophosphamide: risk of graft failure, poor graft function and impact on outcomes. Biol Blood Marrow Transplant. 2019.
Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin JL, Tischer J, Gulbas Z, Wallet HL, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2019.
Autore F, Piccirillo N, Nozza A, Innocenti I, Putzulu R, Chiusolo P, Sora' F, Zini G, Bacigalupo A, Castagna L, et al. Peripheral blood hemopoietic stem cell mobilization regimens in POEMS syndrome: a retrospective study at two haematological Italian centres. Biol Blood Marrow Transplant. 2019.
Mariotti J, Taurino D, Marino F, Bramanti S, Sarina B, Morabito L, De Philippis C, Di Vito C, Mavilio D, Carlo-Stella C, et al. Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. Cancer Med. 2019.
2020
Mariotti J, Penack O, Castagna L. Acute Graft-versus-Host-Disease other than typical targets: between myths and facts. Biol Blood Marrow Transplant. 2020.
De Philippis C, Legrand-Izadifar F, Bramanti S, Giordano L, de Oca CMontes, Duléry R, Bouabdallah R, Granata A, Devillier R, Mariotti J, et al. Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Adv. 2020;4(7):1242-1249.
Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VRuggero, Zanni M, Merli F, Anastasia A, Luminari S, et al. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2020;4(1):136-140.
Bazarbachi A, Labopin M, Angelucci E, Gulbas Z, Ozdoğu H, Arat M, de Rosa L, Pastano R, Pioltelli P, Montserrat R, et al. Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. Biol Blood Marrow Transplant. 2020.
Mariotti J, Raiola AMaria, Evangelista A, Carella AMichele, Martino M, Patriarca F, Risitano A, Bramanti S, Busca A, Giaccone L, et al. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020;4(16):3900-3912.
Ruggeri A, Labopin M, Battipaglia G, Chiusolo P, Tischer J, Diez-Martin JLuiz, Bruno B, Castagna L, Moiseev ISergeevich, Vitek A, et al. The timing of post-transplant cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the ALWP of the EBMT. Biol Blood Marrow Transplant. 2020.
2021
Bramanti S, De Philippis C, Bartoli A, Giordano L, Mariotti J, Sarina B, Mannina D, Valli V, De Gregori S, Roperti M, et al. Feasibility and efficacy of a PK-guided busulfan conditioning regimen for Allogeneic SCT with PTCY as GVHD prophylaxis in adult patients with hematologic malignancies. Transplant Cell Ther. 2021.
Castagna L, Valli V, Timofeeva I, Capizzuto R, Bramanti S, Mariotti J, De Philippis C, Sarina B, Mannina D, Giordano L, et al. Feasibility and Efficacy of CD45RA+ Depleted Donor Lymphocytes Infusion After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide in Patients With Hematological Malignancies. Transplant Cell Ther. 2021.
Sarina B, Mancosu P, Navarria P, Bramanti S, Mariotti J, De Philippis C, Clerici E, Franzese C, Mannina D, Valli V, et al. Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases. Transplant Cell Ther. 2021.
Sahebi F, Eikema D-J, Koster L, Kröger N, Meijer E, van Doesum JA, Rovira M, Koc Y, Angelucci E, Blaise D, et al. Post-Transplant Cyclophosphamide for Graft vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type: A Study from the Chronic Malignancies Working Party of the EBM. Transplant Cell Ther. 2021.
2022
Ruggeri A, Galimard J-E, Labopin M, Rafii H, Blaise D, Ciceri F, Diez-Martin J-L, Cornelissen J, Chevallier P, Sanchez-Guijo F, et al. Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT. Transplant Cell Ther. 2022.
Santoro N, Mooyaart JE, Devillier R, Koc Y, Vydra J, Castagna L, Gulbas Z, Martin JDiez, Araujo MColorado, Kulagin A, et al. Correction: Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party. Bone Marrow Transplant. 2022.
Castagna L, Patti K, Mulè A. Don't forget cord blood in non-remission acute myeloid leukaemia!. Br J Haematol. 2022.

Pages